5-Amino-1MQ is often talked about in peptide circles, but it is not actually a peptide. It is a small-molecule NNMT inhibitor being studied for its potential role in nicotinamide metabolism, NAD⁺ biology, methylation, fat-cell function, insulin sensitivity, and liver metabolism.

In this episode, John Garrett breaks down the proposed mechanism behind 5-Amino-1MQ, why people are discussing it for fat loss and body composition, and what the current research actually shows.

The data is interesting, especially in preclinical studies involving adipocytes, diet-induced obese mice, glucose tolerance, insulin sensitivity, and fatty liver markers. But the human clinical evidence is still limited, and 5-Amino-1MQ is not FDA-approved for fat loss, obesity, metabolic disease, longevity, or body composition.

This episode takes a balanced look at the science, the grey-market reality, and how to think about emerging metabolic compounds responsibly.

This podcast is for informational purposes only and is not medical advice. Always consult a licensed healthcare professional before considering any therapy.

Peptides Explained is powered by Peptide Solutions.

Peptides Explained is also an affiliate partner with Offline Peptides. If you use my link, I may earn a commission at no additional cost to you.

Offline Peptides affiliate link:https://offlinepeptides.com/ref/JohnGarrett/

Podcast website:https://peptidesexplained.info

Peptide Solutions:https://peptide-solutions.info

Episode ID: 1000775596413

GUID: 36ab5216-4ebb-4a62-a84f-4667b54bdaff

Release Date: 06/07/2026, 06:00:00